Z. Machackova
Roche (Switzerland)(CH)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Peptidase Inhibition and Analysis, Cancer Treatment and Pharmacology, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study(2021)67 cited
- → Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study(2017)50 cited
- → IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer(2024)42 cited
- → Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge(2021)25 cited
- → Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial(2017)21 cited
- Radiosensitivity of peripheral blood lymphocytes from healthy donors and cervical cancer patients; the correspondence of in vitro data with the clinical outcome.(2008)
- → 165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study(2020)10 cited
- → 180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)(2024)3 cited
- → Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)(2024)3 cited
- → Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics(2021)3 cited